Apeiron raises €17.5 million for COVID-19 drug

Country

Austria

The Austrian biotech company Apeiron Biologics AG has raised €17.5 million to expand a Phase 2 trial of a candidate drug for COVID-19. The trial has been launched in Austria, Germany, Denmark and the UK, and plans are afoot to open new sites in the US and Russia. The randomised, placebo-controlled study is expected to treat 200 patients with severe COVID-19 disease.